Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8511)
All Articles published online
|
Publishing Process of This Article
|
Dec 14, 2019 (publication date) through Nov 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kim SJ, Chung JW, Woo HS, Kim SY, Kim JH, Kim YJ, Kim KO, Kwon KA, Park DK. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial. World J Gastroenterol 2019; 25(46): 6790-6798 [PMID: 31857780 DOI: 10.3748/wjg.v25.i46.6790] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v25/i46/6790.htm |
| Number | Citing Articles |
| 1 |
Rocco Maurizio Zagari, Elton Dajti, Anna Cominardi, Leonardo Frazzoni, Lorenzo Fuccio, Leonardo Henry Eusebi, Amanda Vestito, Andrea Lisotti, Giuseppe Galloro, Marco Romano, Franco Bazzoli. Standard Bismuth Quadruple Therapy versus Concomitant Therapy for the First-Line Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 2023; 12(9): 3258 doi: 10.3390/jcm12093258
|
| 2 |
David Mathew Thomas, Krishnadas Devadas.
Bismuth‐based quadruple therapy vs concomitant therapy for
Helicobacter pylori
eradication—a real‐world experience
. GastroHep 2021; 3(6): 388 doi: 10.1002/ygh2.486
|
| 3 |
Gyu Young Pih, Kee Don Choi, Eun Jeong Gong, Hee Kyong Na, Ji Yong Ahn, Jeong Hoon Lee, Kee Wook Jung, Do Hoon Kim, Ho June Song, Gin Hyug Lee, Hwoon‐Yong Jung. Modified bismuth quadruple therapy with low‐dose metronidazole as first‐line therapy for Helicobacter pylori infection. Helicobacter 2021; 26(1) doi: 10.1111/hel.12759
|
| 4 |
Caiqi Liu, Yuan Wang, Jiaqi Shi, Chunhui Zhang, Jianhua Nie, Shun Li, Tongsen Zheng. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therapeutic Advances in Gastroenterology 2021; 14 doi: 10.1177/1756284821989177
|
| 5 |
Giuseppe Losurdo, Antonia Valeria Borraccino, Adriana Aloisio, Francesco Russo, Giuseppe Riezzo, Grazia Galeano, Maria Pricci, Bruna Girardi, Francesca Celiberto, Andrea Iannone, Enzo Ierardi, Alfredo Di Leo. Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial. Antibiotics 2024; 13(4): 348 doi: 10.3390/antibiotics13040348
|
| 6 |
Su Young Kim, Jun-Won Chung. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics 2020; 9(8): 436 doi: 10.3390/antibiotics9080436
|
| 7 |
Sung Eun Kim, Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim, Miyoung Choi. A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021; 21(1): 48 doi: 10.7704/kjhugr.2020.0052
|
| 8 |
Diego Reyes, Javier Ortiz, Eduardo Fuentes-López, Sigall Budnik, Vicente Gándara, Andrea Gallardo, María Francisca Seydewitz, Roberto Candia, José Ignacio Vargas, María Paz Rollan, Javiera Godoy, Antonio Rollan, Rodrigo Mansilla, Alex Arenas, Javier Chahuán, Alberto Espino, Margarita Pizarro, Arnoldo Riquelme. Terapias cuádruples son superiores a terapia triple estándar en primera línea de erradicación de Helicobacter pylori en Chile. Gastroenterología y Hepatología 2022; 45(7): 515 doi: 10.1016/j.gastrohep.2021.11.010
|
| 9 |
Logan T. Roberts, Peter P. Issa, Evan S. Sinnathamby, Mallory Granier, Holly Mayeux, Treniece N. Eubanks, Kevin Malone, Shahab Ahmadzadeh, Elyse M. Cornett, Sahar Shekoohi, Alan D. Kaye. Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice. Life 2022; 12(12): 2038 doi: 10.3390/life12122038
|
| 10 |
Yue Fu, Song Zhang, Qiulin Yue, Zaiyong An, Minghan Zhao, Chen Zhao, Xin Sun, Kunlun Li, Baojun Li, Lin Zhao, Le Su. The preventative effects of Lactococcus Lactis metabolites against LPS-induced sepsis. Frontiers in Microbiology 2024; 15 doi: 10.3389/fmicb.2024.1404652
|
| 11 |
Diego Reyes, Javier Ortiz, Eduardo Fuentes-López, Sigall Budnik, Vicente Gándara, Andrea Gallardo, María Francisca Seydewitz, Roberto Candia, José Ignacio Vargas, María Paz Rollan, Javiera Godoy, Antonio Rollan, Rodrigo Mansilla, Alex Arenas, Javier Chahuán, Alberto Espino, Margarita Pizarro, Arnoldo Riquelme. Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. Gastroenterología y Hepatología (English Edition) 2022; 45(7): 515 doi: 10.1016/j.gastre.2022.07.004
|
| 12 |
Manahil Rahat, Muhammad Saqib, Muhammad Ahmed, Muhammad Suleman, Syed M. Ismail, Hassan Mumtaz, Hamna Khalid. Use of eradication therapy in adjunction to periodontal therapy versus alone for treatment of Helicobacter pylori infections: a mini review. Annals of Medicine & Surgery 2023; 85(6): 2756 doi: 10.1097/MS9.0000000000000741
|
| 13 |
Anthony O'Connor, Takahisa Furuta, Javier P. Gisbert, Colm O'Morain. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020; 25(S1) doi: 10.1111/hel.12743
|
| 14 |
Xiaohua Hou, Jiangbin Wang, Qin Du, Dean Tian, Naizhong Hu, Deliang Liu, Fang Zhou, Li Xie, Liqun Gu, Kentarou Kudou, Shutian Zhang. Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of <i>Helicobacter pylori</i> in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials. Biological and Pharmaceutical Bulletin 2024; 47(8): 1405 doi: 10.1248/bpb.b24-00011
|
| 15 |
Joon Sung Kim, Weonjin Ko, Jun‐Won Chung, Tae Ho Kim. Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study. Helicobacter 2023; 28(3) doi: 10.1111/hel.12977
|
| 16 |
Youn I Choi, Jun-Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung Ho Kim, Ja Young Seo, Dong Kyun Park. Tailored eradication strategy <i>vs</i> concomitant therapy for <i>Helicobacter pylori</i> eradication treatment in Korean patients. World Journal of Gastroenterology 2021; 27(31): 5247-5258 doi: 10.3748/wjg.v27.i31.5247
|
| 17 |
Jun-Hyung Cho, So-Young Jin. Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-Line Helicobacter pylori Eradication Using Tegoprazan, Clarithromycin, and Bismuth: A Propensity Score Matching Analysis. Microorganisms 2024; 12(10): 1952 doi: 10.3390/microorganisms12101952
|
| 18 |
Yeon‐Ji Kim, Woo Chul Chung, Dae Bum Kim. Efficacy of bismuth added to standard triple therapy as the first‐line eradication regimen for Helicobacter pylori infection. Helicobacter 2021; 26(3) doi: 10.1111/hel.12792
|
| 19 |
Jun-Hyung Cho.
Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line
Helicobacter pylori
eradication: a real-world evidence study
. Expert Review of Anti-infective Therapy 2024; : 1 doi: 10.1080/14787210.2024.2329251
|
| 20 |
William D. Chey, Colin W. Howden, Steven F. Moss, Douglas R. Morgan, Katarina B. Greer, Shilpa Grover, Shailja C. Shah. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology 2024; 119(9): 1730 doi: 10.14309/ajg.0000000000002968
|
| 21 |
Young-Il Kim, Jong Yeul Lee, Chan Gyoo Kim, Boram Park, Jin Young Park, Il Ju Choi. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01680-1
|
| 22 |
Sotirios Georgopoulos, Vasilios Papastergiou. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opinion on Pharmacotherapy 2021; 22(6): 729 doi: 10.1080/14656566.2020.1845649
|
| 23 |
Erick A. Argueta, Steven F. Moss. Management of Helicobacter pylori. Current Opinion in Gastroenterology 2020; 36(6): 518 doi: 10.1097/MOG.0000000000000678
|
| 24 |
Ting-Ting Huang, Yong-Xiao Cao, Lei Cao. Novel therapeutic regimens against Helicobacter pylori: an updated systematic review. Frontiers in Microbiology 2024; 15 doi: 10.3389/fmicb.2024.1418129
|
| 25 |
Nuttapat Tungtrongchitr, Phubordee Bongkotvirawan, Sarita Ratana-Amornpin, Sith Siramolpiwat, Thanee Eiamsitrakoon, Pornpen Gamnarai, Arti Wongcha-um, Yoshio Yamaoka, Kammal Kumar Pawa, Ratha-korn Vilaichone. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-59621-3
|